Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands.

ABSTRACT:

Background

In the Netherlands, more than one million patients have type 2 diabetes (T2D), and approximately 36% of these patients have chronic kidney disease (CKD). Yearly medical costs related to T2D and CKD account for approximately €1.3 billion and €805 million, respectively. The FIDELIO-DKD trial showed that the addition of finerenone to the standard of care (SoC) lowers the risk of CKD progression and cardiovascular (CV) events in patients with CKD stages 2-4 associated with T2D. This study investigates the cost-effectiveness of adding finerenone to the SoC of patients with advanced CKD and T2D compared to SoC monotherapy.

Methods

The validated FINE-CKD model is a Markov cohort model which simulates the disease pathway of patients over a lifetime time horizon. The model

SUBMITTER: Quist SW 

PROVIDER: S-EPMC10685667 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature